Estrogen and Progesterone in HRT

Estrogen is a group of hormones. Estradiol is one estrogen used in menopause treatment; other preparations contain different estrogens. Progesterone is a hormone made by the body and available as a prescription medicine. Progestogen is the broader term that includes progesterone and synthetic medicines with related actions.

A prescription may therefore name estradiol and micronized progesterone, or estrogen and a synthetic progestogen. 'Micronized' means the progesterone has been processed into smaller particles to improve oral availability. Whether you need a progestogen depends on the uterus and the type of estrogen treatment.

Estrogen can stimulate the endometrium, the lining of the uterus. With systemic treatment, estrogen alone increases the risk of endometrial overgrowth and cancer. A suitable progestogen reduces that risk. This requirement applies whether systemic estrogen comes from a tablet, patch, gel, or spray.

After a total hysterectomy, estrogen alone is generally appropriate if systemic HRT is chosen. If the operation or remaining anatomy is uncertain, the clinician should check the record before selecting the regimen.

Low-dose vaginal estrogen is a different treatment category, with much lower whole-body exposure. Additional progestogen is generally unnecessary with standard low-dose local therapy. The exact product needs checking because some vaginal rings deliver systemic estrogen. Unexpected bleeding still needs assessment.

Continuous combined HRT supplies estrogen and progestogen continuously, aiming to avoid scheduled bleeding. Cyclic or sequential treatment supplies progestogen for part of the month, commonly followed by a withdrawal bleed. Cyclic treatment is often considered during perimenopause; continuous treatment is commonly used after menopause.

The estrogen dose, chosen progestogen, menstrual stage, and bleeding history affect the prescription. Follow the written schedule for the exact product. The progesterone capsule label includes a specific cyclic regimen for endometrial protection, but that schedule should not be applied automatically to every estrogen prescription.

A combined tablet or patch includes both hormones. Separate products offer different practical choices, but create an additional schedule to follow. An intrauterine progestogen is used in some plans; its role for endometrial protection with estrogen is off-label in the United States and needs a specific discussion.

Progestogens can cause breast tenderness, nausea, mood changes, tiredness, or dizziness. With a cyclic regimen, record whether symptoms repeatedly coincide with those days. The prescriber can review a different progestogen, schedule, or overall treatment if tolerance is poor.

The cited US progesterone capsule label advises taking it at bedtime because transient dizziness and drowsiness can occur. It also contains peanut oil, so its ingredients matter for someone with peanut allergy. Check the leaflet for the exact dispensed product; formulations can differ.

The word 'bioidentical' does not establish lower risk

FDA-approved estradiol and progesterone are available. ACOG recommends approved treatment over routine compounded hormone therapy. NICE finds insufficient evidence to establish whether micronized progesterone has a different breast cancer risk from other progestogens. That uncertainty should be part of an informed choice.

The progesterone capsule label includes endometrial protection with estrogen and a separate use for secondary amenorrhea, meaning absent periods in someone who previously menstruated. The reason for treatment affects the regimen. A menopause prescription should explain whether progesterone is being used for uterine protection, another licensed indication, or an off-label purpose.

Sleepiness after a capsule does not establish that progesterone is the appropriate treatment for persistent insomnia. If sleep problems remain, assess nighttime heat, insomnia, sleep apnea, mood, and other possible contributors. Likewise, a progestogen prescribed for lining protection does not supply the same treatment as systemic estrogen for hot flashes.

• Name the estrogen and explain whether its dose is systemic or local.
• Confirm whether a uterus is present and how its lining will be protected.
• Write down the progestogen days, expected bleeding pattern, and missed-dose instructions.
• Discuss allergies, drowsiness, mood effects, and medicines that may complicate the schedule.

Report new or persistent unscheduled bleeding and arrange the recommended review. A suitable regimen has to work for both symptom control and ongoing safety.